Extrait
This extension II study will allow for further follow-up of the disease under treatment with imatinib mesylate and allow the patients to continue to receive imatinib mesylate.
Critère d'inclusion
- Philadelphia Positive Chronic Myeloid Leukemia in Myeloid Blast Crisis